Abbvie (ABBV) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The AbbVie (ABBV) PHASES study, officially titled “Prodrome in tHe reAl World: aSsESsing Ubrogepant Acute Use,” tracks how well ubrogepant works when taken early in a migraine attack. It focuses on real-world use in adults and aims to show if earlier treatment can reduce attack severity and improve daily function.
The study evaluates ubrogepant, an oral migraine drug already approved for acute use in adults. The goal is to see how this pill performs in everyday practice when patients take it during the prodrome phase, before head pain fully develops.
This is an observational, real-world cohort study with a prospective design rather than a randomized trial. Patients receive ubrogepant as prescribed by their own doctors, and researchers then track outcomes over time without changing standard care.
The trial plans to enroll about 189 adults at roughly 15 U.S. sites, with follow-up up to 13 weeks per participant. Key dates include the initial submission on 2025-12-16 and the latest update on 2026-02-09, signaling active study management and ongoing data collection.
For investors, this update supports AbbVie’s push to strengthen its migraine franchise beyond traditional injectables and triptans. Positive real-world evidence could support broader physician adoption, extend ubrogepant’s use case, and reinforce AbbVie’s position versus rivals in acute migraine such as Pfizer, Eli Lilly, and Biohaven.
The study remains active and updated on the ClinicalTrials portal, where further details and future results will be available as the program progresses.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.